NCT01482611View on ClinicalTrials.gov

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

JNJ-47910382

Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.

DRUG

JNJ-47910382

Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.

DRUG

JNJ-47910382

Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.

DRUG

JNJ-47910382

Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.

DRUG

Placebo

Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.

DRUG

Placebo

Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use

DRUG

Placebo

Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.

DRUG

Placebo

Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use

Trial Locations (1)

Unknown

Neuss

All Listed Sponsors
lead

Janssen R&D Ireland

INDUSTRY

NCT01482611 - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 | Biotech Hunter | Biotech Hunter